secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000950170-25-100902
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q2 2025 net loss widens to $42.7M; cash $237.9M; Phase 3 trials on track
--------------------------------------------------------------------------------

- Net loss of $42.7M in Q2 2025 vs $5.9M in Q2 2024, driven by higher R&D and warrant fair value changes.
- Cash, cash equivalents and investments totaled $237.9M as of June 30, 2025, sufficient into 2027.
- R&D expenses rose to $29.8M from $14.6M YoY, primarily due to MM120 ODT program advancement.
- Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) and Emerge (MDD) data in 2H 2026.
- Appointed Brandi L. Roberts as CFO, bringing over 25 years of life sciences financial leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/0000950170-25-100902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-100902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer